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Summary
Background: The status of complementary and alternative medi-
cine (CAM) within the EU needs clarification. The definition and ter-
minology of CAM is heterogeneous. The therapies, legal status, 
regulations and approaches used vary from country to country but 
there is widespread use by EU citizens. A coordination project 
funded by the EU has been launched to improve the knowledge 
about CAM in Europe. Objectives and Methods: The project aims to 
evaluate the conditions surrounding CAM use and provision in Eu-
rope and to develop a roadmap for European CAM research. Spe-
cific objectives are to establish an EU network involving centres of 
research excellence for collaborative projects, to develop consen-
sus-based terminology to describe CAM interventions, to create a 
knowledge base that facilitates the understanding of patient de-
mand for CAM and its prevalence, to review the current legal status 
and policies governing CAM provision, and to explore the needs 
and attitudes of EU citizens with respect to CAM. Based on this in-
formation a roadmap will be created that will enable sustainable 
and prioritised future European research in CAM. CAMbrella en-
compasses 16 academic research groups from 12 European coun-
tries and will run for 36 months starting from January 2010. The 
project will be delivered in 9 work packages coordinated by a Man-
agement Board and directed by a Scientific Steering Committee 
with support of an Advisory Board. Output: The outcomes gener-
ated will be disseminated through the project’s website, peer re-
view open access publications and a final conference, with empha-
sis on current and future EU policies, addressing different target 
audiences.
Schlüsselwörter
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Zusammenfassung
Hintergrund: Die Situation der Komplementärmedizin (CAM) in der 
EU bedarf der genaueren Betrachtung. Die Definition von CAM und 
die verwendete Terminologie sind uneinheitlich. Rechtsstatus und 
Regulierung sowie die eingesetzten Therapieverfahren und Metho-
den variieren von Land zu Land, während CAM EU-weit häufig ge-
nutzt wird. Ein von der EU finanziertes Koordinierungsprojekt 
wurde gestartet, um den Kenntnisstand bezüglich der Situation von 
CAM in Europa zu verbessern. Ziele und Methoden: Ziel des Projek-
tes ist die Beschreibung der Bedingungen rund um Gebrauch und 
Angebot von CAM in Europa sowie die Entwicklung einer Agenda 
für künftige europäische CAM Forschung. Weitere Ziele sind, ein 
EU-weites Netzwerkes von Forschungszentren für künftige Gemein-
schaftsprojekte einzurichten, eine übereinstimmende Terminologie 
zur Beschreibung von CAM-Interventionen zu entwickeln, das Wis-
sen um Nachfrage und Verwendung von CAM zu verbessern, die 
derzeitige Gesetzeslage und Regulierung von CAM darzustellen 
sowie die Bedürfnisse und Einstellungen der EU-Bürger bezüglich 
CAM zu beleuchten. Auf dieser Grundlage soll ein Plan für rele-
vante und nachhaltige europäische CAM-Forschung entwickelt wer-
den. CAMbrella umfasst 16 akademische Forschungsgruppen aus 
12 europäischen Ländern und läuft seit Januar 2010 über einen 
Zeitraum von 36 Monaten. Das Projekt, das in 9 Arbeitsgruppen 
aufgeteilt ist, wird von einem Management-Team unter der Leitung 
eines wissenschaftlichen Lenkungsausschusses koordiniert und 
durch einen Beirat unterstützt. Output: Die erzielten Ergebnisse 
werden kommuniziert mittels der Homepage des Projekts, durch 
frei zugängliche hochrangige wissenschaftliche Publikationen und 
im Rahmen einer Abschlusskonferenz mit Berücksichtigung ver-
schiedener Zielgruppen und der möglichen Auswirkungen auf der-
zeitige und künftige EU-Politik.
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In public health, the prevalence of use of CAM interven-
tions is a key issue. The utilisation of specific methods such 
as acupuncture, homeopathy, herbal medicine, massage, re-
flexology and Reiki healing has increased exponentially in 
Western industrialized nations over the last 25 years [4, 
7–9]. The World Health Organisation (WHO) Centre for 
Health Development published a global atlas of traditional, 
complementary and alternative medicine comprising a text 
and a map volume [10]. The WHO concluded that CAM is 
highly prevalent in the European region but was unable to 
draw a clear picture of CAM use across the whole EU as the 
evidence available was drawn from just a few member 
states. There is an urgent need to gather more information 
to gain an overview of the issues surrounding CAM, its 
availability and its safe and legitimate provision to EU citi-
zens. There are currently no reliable comparisons between 
EU member states because they use different definitions 
with respect to CAM and the associated treatment methods 
[11]. EU-wide consensus in this field is essential to develop 
an understanding of EU citizens’ behaviour with respect to 
CAM and to establish appropriate health policies in this 
area.
Objectives
In accordance with the call for proposals published on Sep-
tember 3, 2008 by the EC for the FP7-Health-2009 work pro-
gramme [12], CAMbrella is designed to fulfil the following 
specific objectives:
– To develop consensus on a series of definitions for the ter-
minology used to describe the major CAM interventions 
used clinically in Europe.
– To create a knowledge base that allows us to accurately 
evaluate the patient demands for CAM and the prevalence 
of its use in Europe.
– To review the current legal status of CAM in EU member 
or associated states.
– To explore the needs and attitudes of EU citizens with 
 respect to CAM.
– To explore the providers’ perspectives on CAM treatment 
in Europe.
– To propose an appropriate research strategy for CAM that 
will help develop an understanding of CAM use and its 
 effectiveness within an EU context in response to the 
needs of healthcare funders, providers and patients. This 
will take account of the issues of effectiveness, cost, safety 
and the legal requirements for the production of medicinal 
substances.
– To develop a process for prioritizing future EU research 
strategy, the current policies within the EU have to be 
considered.
– To facilitate and foster sustainable, high quality collabora-
tion and networking of European CAM researchers.
Introduction and Rationale
The status of complementary and alternative medicine 
(CAM) in Europe is characterized by enormous heterogene-
ity in all aspects. This includes the terminology used, the 
methods provided, the prevalence, as well as the national 
legal status and regulation [1, 2]. The diversity and plurality of 
opinions and attitudes towards CAM, even within a relatively 
small academic CAM community, renders a coordinated 
 European approach to CAM research difficult. Consequently, 
a comprehensive coordination action presents a thoughtful 
strategic response to this challenge. 
Europe-based research in this field is limited because of the 
restricted funding available; for instance in the UK 0.0085% of 
medical research funds are spent on CAM research. By con-
trast, more than 10% of the UK population use CAM each 
year and approximately 50% are lifetime users [3]; in Ger-
many, as another example, 1-year prevalence of use is reported 
to be around 60% [4]. European and international recommen-
dations (World Health Assembly and Beijing Declaration) 
with respect to CAM support the urgent need for further stra-
tegic research to enable appropriate decision making (EP A6–
0379/2006, Decision No. 1350/2007/EC; WHO Fact Sheet No. 
134, 2008). Outside of Europe, the National Center for Com-
plementary and Alternative Medicine (NCCAM) is consid-
ered the leading institution providing an annual budget of 
 approximately $ 120 million for CAM research. 
Previous CAM projects funded by European authorities 
include ‘COST B4’, a project on unconventional medicine in 
Europe set up by the European Commission (1993–1998). It 
rendered findings on socio-cultural aspects, research method-
ology and dialogue between unconventional and orthodox 
medicine, and made recommendations for future work in this 
field [5]. However, the complex and ambitious recommenda-
tions were not implemented in EU or national research strat-
egy, restricting the long-term impact of COST B4 to providing 
a clear strategic concept. The project ‘Concerted Action for 
Complementary and Alternative Medicine Assessment in the 
Cancer Field’ (CAM-Cancer, Project No. QLG4-CT-2002– 
00786) was launched under FP5 (2002–2005). It aimed at pro-
viding information and building an international network 
around CAM in cancer. It is now hosted by one of the par-
ticipants of CAMbrella (NAFKAM) to ensure sustainable 
benefit. 
Unlike these projects, CAMbrella is the first EU frame-
work programme coordination action that is explicitly related 
to CAM in general and not focused on a specific condition. 
Besides this, the view currently taken in European health 
 policy is also pointed out in Decision No. 1350/2007/EC which 
stipulates that the Second Programme of Community Action 
in the Field of Health ‘should recognise the importance of a 
holistic approach to public health’ and that CAM should be 
taken into account in its actions ‘where appropriate and 
where there is scientific or clinical evidence’ [6]. 
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EU member states (fig. 1). Further criteria were previous 
 experience in international cooperation and a neutral position 
with respect to individual treatment methods or the interests 
of manufacturers of natural health products. The project is 
 assisted by an advisory board in order to obtain input from 
the diverse CAM stakeholder groups including consumers, 
practitioners, clinical providers, and manufacturers of CAM 
medicinal products (table 2). Most of the institutions that 
have joined the board are umbrella organizations which oper-
ate at European level and thus represent a significant number 
of members. The board members provide advice on health-
care and technical and political issues, thereby complement-
ing the scientific perspective of the consortium.
Work Plan
The project’s work plan is divided into a total of 9 work pack-
ages (WPs), comprising content-related WPs (WP1–WP7), 
one for disseminating the project results (WP8) and one dedi-
Consortium
To achieve the project’s goals, a consortium was established 
which encompasses 16 partners predominantly affiliated to 
universities from 12 European countries with nearly 40 scien-
tists and experts in research and clinical practice directly in-
volved (table 1). CAMbrella is coordinated and monitored by 
a management board and directed by a scientific steering 
committee with support of an advisory board and involves all 
the major stakeholders in CAM research in Europe. In addi-
tion to the authors of this article, the consortium includes 
Francesco Cardini (Italy), Gérard Delahaye (France), Simona 
Dragan (Romania), Gabriella Hegyi (Hungary), Paolo Rob-
erti di Sarsina (Italy) and Jorge Vas (Spain). The current com-
position of the consortium is the result of a dynamic process 
initiated by an ad-hoc working group in December 2006. Fur-
ther participants have been included during the preparatory 
phase of the project. Inclusion criteria were the participants’ 
qualification with respect to the overall objective of the 
project and a preferably broad geographical representation of 
Table 1. List of cooperation partners forming the CAMbrella consortium 
Beneficiary name – short name Country Staff involved
 1 Technische Universität München – Klinikum rechts der Isar (Coordinator) –  
MRIa
Germany W WeidenhammerMB,SSC, M Schagerl
 2 Wiener Internationale Akademie für Ganzheitsmedizin – GAMED Austria B ReiterSSC, S. Zopf
 3 Universitetet i Tromsø – NAFKAMa Norway V FønnebøSSC, S Wiesener, 
L Salomonsen
 4 Universität Bern – UNIBEa Switzerland K von AmmonSSC, M Frei-Erb
 5 University of Southampton – USa UK G LewithSSC, F Bishop, S Eardley, M Jong
 6 Charité – Universitätsmedizin Berlin – Charitéa Germany B BrinkhausMB,SSC, D McBride, F Junne, 
F. Fischer
 7 Universität Zürich – UZHa Switzerland B UehlekeSSC, J Melzer, H-W Hoefert
 8 Comitato Permanente di Consenso e Coordinamento per le Medicine  
Non-Convenzionali in Italia – ComCAM
Italy P Roberti di Sarsina, I Iseppato
 9 Karolinska Institutet – KIa Sweden T FalkenbergSSC, J Hoek
10 Université Paris 13 – SMBHa France G Delahaye, P Escure, A. Lazarus
11 Servicio Andaluz de Salud – SAS Spain J Vas, K Santos Rey
12 Agenzia sanitaria e sociale regionale – Regione Emilia-Romagna – ASSR Italy F Cardini, S Florindi
13 Pécsi Tudományegyetem – University of Pecs – PTEa Hungary G Hegyi
14 Universitatea de Medicina si Farmacie Victor Babes Timisoara – UMFTa Romania S Dragan, S. Ursoniu
15 Syddansk Universitet – SDUa Denmark H JohannessenSSC, N Nissen, J Sørensen, 
J Madsen
16 Bayerische Forschungsallianz gemeinnützige GmbH – BayFOR Germany F Baumhöfener, M DlabohaMB
aAffiliated to university.
MBMember of Management Board.
SSCMember of Scientific Steering Committee.
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of citizens and providers as well as the legal status and regu-
lation. Their findings and results constitute the basis for the 
concluding WP7 which will develop a roadmap for future 
 European CAM research as one of the central outcomes of 
cated to the project management (WP9). WPs 1 through 6 
consider the current status of CAM in Europe and review the 
literature with respect to the major aspects of CAM such as 
terminology, methods, prevalence of use, needs and demands 
Fig. 1. Regional distribution and major expertise of the CAMbrella project partners.
Table 2. List of members of the Advisory Board
Organization Abbreviation Website
Association of Natural Medicine in Europe ANME www.anme.info
European Central Council of Homeopaths ECCH www.homeopathy-ecch.org
European Coalition on Homeopathic and Anthroposophic Medicinal Products ECHAMP www.echamp.org
European Committee for Homeopathy ECH www.homeopathyeurope.org
European council of doctors for plurality in medicine ECPM www.ecpm.org 
European Forum for Complementary and Alternative Medicine EFCAM www.efcam.eu
European Herbal and Traditional Medicine Practitioners’ Association EHTPA www.ehpa.eu
European Information Centre for Complementary and Alternative Medicine EICCAM www.eiccam.eu
European Public Health Association EPHA www.epha.org
International Council of Medical Acupuncture and Related Techniques ICMART www.icmart.org
International Federation of Anthroposophic Medical Associations IVAA www.ivaa.eu
Kneipp-Bund eV KB www.kneippbund.de 
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will also draw on the experience from international activities 
in the field of CAM and include international organizations in 
our dissemination activities in order to generate relevant 
feedback. The stakeholders included are recognized as repre-
sentatives of specific regions (such as Asia, North America, 
South and Latin America and the Western Pacific Region), 
national organizations (e.g. NIH/NCCAM, the State Admin-
istration of Traditional Chinese Medicine of the People’s Re-
public of China and nationally appointed CAM Research and 
Development (R and D) centres), relevant non-governmental 
organisations (e.g. Cochrane Collaboration, the Osher 
 Centers for Integrative Medicine, the Samueli Institute, and 
leading world federations of CAM therapies) and authori-
tative multilateral organizations (such as WHO/HTP/TRM, 
UNICEF and the World Bank).
the CAMbrella project. For a detailed list of the objectives of 
all WPs see table 3. The content-related WPs have clear inter-
dependencies and proceed in a timely interlaced manner. The 
majority of the WPs will deliver their outputs in the form of 
written reports which will be published in peer-reviewed 
 journals and will be accessible to the public. 
One of the major tasks of the CAMbrella coordination 
 action is to establish a reliable European network extending 
beyond the project consortium. The main centres of excel-
lence in the field have been invited to cooperate. Face-to-face 
meetings between the partners will facilitate the exchange of 
ideas and thus enhance sustainable relations among the con-
sortium members. Communication as well as the administra-
tive project management is supported by the software tool 
Projectplace™ providing access for all project members. We 
Table 3. Brief description of the objectives of CAMbrella Work Packages 1–9, (L) indicates the Work Package leader position
WP1: Terminology and definitions of CAM methods
Work group members: UZH (L), US, ComCAM, KI, SMBH, SAS
– Identifying and analyzing the existing terms and definitions of CAM used in scientific publications.
– Providing a core set of CAM disciplines and methods being used consistently all over Europe and an additional list of country-specific  
CAM  disciplines and methods.
– Developing a proposal for a practical pan-European definition of CAM, its disciplines and respective methods. 
WP2: Legal status and regulations
Work group members: NAFKAM (L), ComCAM, KI, SMBH, PTE
Report on the current status with respect to:
– legal status of CAM
– regulatory status and governmental supervision of CAM practices
– reimbursement status of CAM practices and medicinal products
– regulation of CAM medicinal products
– status of EU-wide regulation of CAM practices and medicinal products 
– potential obstacles for EU-wide regulation of CAM practices and medicinal products.
WP3: Needs and attitudes of citizens
Work group members: SDU (L), GAMED, MRI, SMBH
– To identify cross-European indicators for population-based needs and attitudes regarding CAM.
– To identify and map the needs of European citizens with respect to CAM.
– To identify and map EU citizens’ attitudes towards CAM.
– To provide information on citizens’ needs and attitudes regarding CAM.
WP4: CAM use – the patients’ perspective
Work group members: US (L), GAMED, NAFKAM, Charite, UZH, SAS, ASSR, PTE, UMFT
– Identify a standardised questionnaire for CAM use.
– Address the prevalence of CAM use in Europe.
– Identify the major conditions treated with CAM.
– Explore the reasons why patients choose CAM.
WP5: CAM use – the providers’ perspective
Work group members: UNIBE (L), US, ComCAM, ASSR, PTE, UMFT, SDU
To identify the different models of CAM provided in European public health systems
– by registered physicians and CAM practitioners
– by country
– in relation to other international perspectives.
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WP6: CAM use – the global perspective
Work group members: KI (L), MRI, NAFKAM, US, SAS
– To incorporate experiences from countries in which CAM R and D is integrated and publicly supported (US/Canada), while exploring its use  
as Traditional Medicine in developing countries. 
– To understand the pros and cons of CAM R and D internationally addressing issues of patient rights and needs, cost, regulation, evidence base 
and research policy/strategy.
– To investigate risks of over-harvesting medicinal plants, and protection of traditional inherited knowledge of traditional medicine used within 
CAM. 
– To identify the R and D strategies to be addressed from an EU perspective. 
WP7: Roadmap for future CAM research
Work group members: Charite (L), MRI, NAFKAM, UNIBE, US, UZH, ASSR, SDU
– Analysis of the research methods already used to identify prevalence and use of CAM in the EU.
– Develop research methods and strategies for CAM that take into account the needs and attitudes of EU citizens and providers (funders and 
 clinicians).
– Develop research strategies and a roadmap to enable future CAM research regarding effectiveness, efficacy, cost effectiveness and safety.
WP8: Dissemination and communication
Work group members: GAMED (L), MRI, SDU, BayFOR
– To foster project internal communication and external communication with CAM stakeholders including patient and public healthcare 
 organizations.
– To establish, host and maintain a website as the common platform for CAMbrella (www.cambrella.eu).
– To identify CAM stakeholders and appropriate target audiences in Europe through which to disseminate information generated by the project.
– To plan and organize the final CAMbrella conference. 
WP9: Management
Work group members: MRI (L), Charite, BayFOR
– To ensure smooth and efficient project implementation and achievement of all project objectives.
– To provide daily coordination and management for the entire project.
– To provide administrative support to all participants.
– To ensure financial regularity and ethics compliance.
– To identify obstacles to running and managing the project (risk management).
– To ensure sustainability of the established network.
– To report to the European Commission.
Timeline
The Grant Agreement with the EC, which includes the final 
Description of Work, was duly signed on October 22, 2009 
and stipulates the project’s duration from January 1, 2010 to 
December 31, 2012. The timeline for the WPs shows that most 
work groups will finish their tasks by the end of 2011, allowing 
for the development of the research roadmap. The key events 
are the kick-off meeting which was held in Munich on January 
21–22, 2010, and the final conference which is planned for 
 November 2012 in Brussels.
Dissemination
The central platform for the dissemination of the information 
generated by CAMbrella is the project website (www.cam-
brella.eu) which is established, hosted and maintained by WP 
8. It offers information on the current status of the project, its 
progress and the work plan for upcoming project milestones. 
The website will also be used as an instrument for disseminat-
ing reports and WP activities. The website will encourage and 
stimulate dialogue between the project consortium and inter-
ested parties, including the publication of a regular newsletter 
that combines information on the project with information on 
relevant CAM research results. 
Comments
The CAMbrella project is a work in progress and will identify 
CAM stakeholders and appropriate target audiences in Eu-
rope through which to disseminate information generated by 
the project. The impact achieved by its developments and 
 outcomes is multi-faceted:
i)  The scientific perspective: The project’s WPs are designed 
to enhance the knowledge of CAM in the EU by develop-
ing consensus on terminology and collecting information 
Table 3. Continued
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most prevalent and relevant for EU citizens and thus eligible 
for future funding by the EC. It has been suggested that the 
strategy in CAM research should be developed in an order 
that differs from that commonly used for conventional medi-
cine [13]. Such a strategy does not contain new methodological 
concepts, but organises existing ideas in a way that is tailored 
to pragmatic clinical practice. It is a framework to guide CAM 
research, illustrating the necessary building blocks  required for 
a sound evidence base. Within this 5-phase research frame-
work, pragmatic trials are proposed as a valuable complement 
to placebo-controlled studies as they focus on routine clinical 
settings and practice [14]. Intervention approaches such as 
psychotherapy and other more complex  interventions includ-
ing CAM may be slightly modified in these contexts [15]. All 
of these methodological issues will be considered in our pro-
posed strategic approach. The outcome of the CAM-focused 
CAMbrella project is designed to contribute to the process 
of developing an appropriate strategy for better healthcare in 
Europe. This will be soundly evidence-based and is likely to 
involve a wide range of different interventions.
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about CAM use, demand for CAM and the legal regula-
tions on CAM provision. Further objectives are to identify 
major conditions treated with CAM and to explore the rea-
sons why patients choose CAM. Based on the available 
 information, a reasonable roadmap for future research 
projects will be suggested to fill the existing knowledge 
gaps and to facilitate that CAM practice is based on appro-
priate evidence. All actions intend to inform EU policies 
and decision makers in order to identify and support re-
search programs of excellence and ensure a solid evidence 
base for the delivery of all aspects of healthcare to Euro-
pean citizens.
ii)  The coordination perspective: The project will create a 
 coordinated EU network of researchers and stakeholders 
within the EU and beyond its borders. This network will 
also foster dialogue with patients, research and healthcare 
funders (both public and private) and specific provider 
groups such as homeopaths and acupuncturists. Various 
organisations, including those representing conventional 
medicine or patients’ interests in general, are being en-
couraged to participate in the project. The information 
generated by the university-based, research-focused core 
of the collaboration will thus have a substantial and strong 
impact on how CAM is looked at and provided in the EU’s 
diverse healthcare systems.
With respect to the limited project time it is particularly im-
portant to look for sustainable network structures. A recently 
established European chapter within the International Society 
for CAM Research (ISCMR, www.iscmr.org) provides an in-
frastructure which can facilitate future use of the network 
 developed by CAMbrella. Such cooperation is also aimed at 
paving the way for further research projects funded by the 
EU’s framework programmes (FP 7, as well as FP 8 starting 
in 2014), while simultaneously providing a pool of linked re-
search centres for collaborative projects.
The roadmap for future European CAM research will be 
based on our understanding of which research activities are 
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